




- (51) **International Patent Classification:** Not classified
- (21) **International Application Number:**
PCT/US2014/050076
- (22) **International Filing Date:**
7 August 2014 (07.08.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/865,755 14 August 2013 (14.08.2013) US
- (71) **Applicant:** PRIMERADIX, INC. [US/US]; Suite 200, 171 Forbes Boulevard, Mansfield, Massachusetts 02048 (US).
- (72) **Inventors:** NOLLING, Jork; 194 Dutcher Street, Hopedale, Massachusetts 01747 (US). DIVAKAR, Kiran Madanahally; 27 Mercury Drive, Shrewsbury, Massachusetts 01545 (US).
- (74) **Agents:** FITZGERALD, Mark J. et al.; Nixon Peabody LLP, 100 Summer Street, Boston, Massachusetts 02110 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KN, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) **Title:** COMPOSITIONS AND METHODS FOR MULTIMODAL ANALYSIS OF CMET NUCLEIC ACIDS



Data were normalized to reference genes SOD1/SPG21 and expressed in fold change
SNU-5 and H1993 show significant amplification and overexpression of cMET
No amplification/overexpression of EGFR

(57) **Abstract:** Described herein are methods and assays relating to the detection of cMET alterations (e.g. variations in copy number and expression level, and/or the presence of mutations, including point mutations). Existing methods are limited in their clinical usefulness by, e.g., limited sensitivity, inter-lab discordance, or inability to provide the necessary multiplex ability. The methods and assays provided herein permit multimodal, multiplex assaying for faster, more cost-effective testing and screening of patients, permitting improved healthcare.

Figure 6

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*